Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 1.7400 |
| Open | 1.7600 |
| Bid | 0.0000 x 2900 |
| Ask | 0.0000 x 3000 |
| Day's range | 1.7300 - 1.8100 |
| 52-week range | 1.6000 - 13.5000 |
| Volume | |
| Avg. volume | 138,458 |
| Market cap | 14.501M |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 08 Nov 2022 - 14 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.00 |
- GlobeNewswire
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomized withdrawal period of Study C602, an ongoing open-label extension study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS). “Initiation of the randomized withdrawal per
- Zacks
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
- Zacks
KemPharm (KMPH) Up On Positive Data From Sleep Disorder Study
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.
